Drug Profile
Metronidazole - Appili Therapeutics
Alternative Names: ATI 1501; LIKMEZLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Appili Therapeutics
- Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Skin disorder therapies; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Amoebiasis; Anaerobic infections; Trichomoniasis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Anaerobic-infections(In volunteers) in Canada (PO, Suspension)
- 30 Nov 2023 Launched for Amoebiasis (In adolescents, In children, In infants, In neonates, In adults) in USA (PO) - First global launch
- 30 Nov 2023 Launched for Anaerobic infections in USA (PO) - First global launch